JPRN-jRCTs031180220已完成未知
Treatment of refractory autoimmuno blistering disease with rituximab
Kanaoka Miwa0 个研究点目标入组 10 人开始时间: 2019年3月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
Rituximab treatment of refractory pemphigus vulgaris resulted in a reduction in steroid dosage after 1 year and improvement in clinical symptoms and antibody titer.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 80age old（—）
- 性别
- All
入选标准
- •Patients who were diagnosed with pemphigus vulgaris, paraneoplastic pemphigus, bullous pemphigoid, with sufficient explanation and obtained research consent as sentences.
排除标准
- •Patients diagnosed as inappropriate by the judgment of the doctor.
研究者
相似试验
进行中（未招募）
2 期
IVIG With Rituximab vs Rituximab as First Line Treatment of PemphigusPemphigusNCT04400994The University of Hong Kong20
已完成
2 期
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for PemphigusPemphigusNCT00656656University of Luebeck23
已完成
1 期
Rituximab in the Treatment of Patients With Bullous PemphigoidBullous PemphigoidNCT00286325Duke University8
已完成
1 期
Clinical Trial Evaluating Rituximab in Ocular Cicatricial PemphigoidOcular Cicatricial PemphigoidNCT00584935University of Alabama at Birmingham3
Unknown
4 期
Low-dose Glucocorticoid Vasculitis Induction StudyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisWegener GranulomatosisMicroscopic PolyangiitisNCT02198248Chiba University140